SRPT NEWS: Did Sarepta Therapeutics Mislead Investors? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al. , No. 25-cv-05317.
Why Was Sarepta Sued for Securities Fraud?
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.
In truth, Elevidys causes fatal acute liver failure in some patients.
The Stock Declines as the Truth Is Revealed
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.'
Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.
Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
What Can You Do?
If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action
Or contact:Ross Shikowitz
[email protected]
212.789.3619
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Afya Limited Announces a New Share Repurchase Program
BELO HORIZONTE, Brazil--(BUSINESS WIRE)-- Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to market and business conditions, levels of available liquidity, cash requirements for other purposes, regulatory, and other relevant factors. The share repurchase program will take place in accordance with the conditions established by the Board of Directors on August 13, 2025. Afya intends to repurchase the shares for use in its stock option program, consideration in futures business combinations transactions and general corporate purposes. Afya's Board of Directors will review the share repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the program. Afya expects to utilize its existing funds and future dividends to be received from Afya Participações to fund repurchases made under this program. It is Afya's intention that such purchases benefit from the safe harbor provided by Rule 10b-18 ('Rule 10b-18') promulgated by the Securities and Exchange Commission (the 'SEC') under the Securities Exchange Act of 1934, as amended. Accordingly, Afya shall not take, nor permit any person or entity under its control to take, any action that could jeopardize the availability of Rule 10b-18 for purchases under the program. About Afya Limited (Nasdaq: AFYA, B3: A2FY34) Afya is a leading medical education group in Brazil based on the number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and offering medical practice solutions to help doctors enhance their healthcare services through their whole career.
Business Wire
4 hours ago
- Business Wire
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, which was announced on July 28, 2025, and earned after Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Any subsequent milestones earned will continue to be payable in cash. Sarepta previously owned 11,926,301 shares of Arrowhead stock. Today after market close, Sarepta sold the balance of its remaining holdings of Arrowhead common stock in a separate negotiated block trade. With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential Share 'We are committed to supporting our broad and long-term collaboration and we are thrilled with the great progress we've made on multiple important clinical, preclinical, and discovery stage siRNA programs. While we remain confident that Sarepta will meet its financial obligations to Arrowhead, we believe reducing our outstanding shares by receiving approximately half of the $100 million due from Sarepta in cash and half in Arrowhead stock to be returned to treasury is a compelling opportunity,' said Christopher Anzalone, Ph.D., Arrowhead's President and CEO. 'With a strong balance sheet anticipated to fund our company into fiscal 2028, we believe this direct stock buyback of Arrowhead shares from Sarepta is an attractive option, given Arrowhead's current stock price and the significant growth potential, both near- and longer-term, as we pursue multiple commercial launches of wholly-owned and partnered candidates in the coming quarters and years.' About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'will,' 'expect,' 'believe,' 'anticipate,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'continue,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including the timing of achievement of future milestones, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements, including our ability to achieve such milestones on projected timelines (if at all) and receive timely payment if milestones are achieved; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties; and our estimates for our projected cash runway. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We disclaim any intention to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
Business Wire
4 hours ago
- Business Wire
Verde Clean Fuels, Inc. Reports Q2 2025 Results
HOUSTON--(BUSINESS WIRE)--Verde Clean Fuels, Inc. ('Verde' or 'the Company') (NASDAQ: VGAS) today reported results for the second quarter and first half of 2025. 'We continue to advance our plans to deploy our proprietary liquid fuels processing technology through the development of commercial production plants. To this end, we also continue to advance front-end engineering and design ("FEED") for the Permian Basin project, a proposed natural gas-to-gasoline plant to be jointly developed with Cottonmouth, a wholly owned subsidiary of Diamondback. The proposed plant would utilize our technology and associated natural gas from Diamondback's operations. We also continue to identify and evaluate other potential opportunities to deploy our technology while remaining disciplined with our resources,' said Ernest Miller, CEO of Verde. For the three months ended June 30, 2025, the Company recorded a net loss of $(2.5) million and diluted net loss per share of Class A common stock of $(0.07). For the six months ended June 30, 2025, the Company recorded a net loss of $(5.2) million and diluted loss per share of Class A common stock of $(0.15). The Company's net loss for the three and six months ended June 30, 2025 was primarily due to ongoing general and administrative expenses. As of June 30, 2025, the Company had cash and cash equivalents of $62.1 million and no debt. Also as of June 30, 2025, the Company had capitalized $2.2 million of FEED costs related to the proposed Permian Basin project, net of amounts reimbursable under the joint development agreement between Verde and Cottonmouth. About Verde Clean Fuels, Inc. Verde is a clean fuels company focused on the deployment of its innovative and proprietary liquid fuels processing technology through development of commercial production plants. Verde's synthesis gas ("syngas")-to-gasoline plus (STG+ ®) process converts syngas, derived from diverse feedstocks, into fully finished liquid fuels that require no additional refining. Verde is currently focused on opportunities to convert associated natural gas into gasoline, which is expected to provide a market for such natural gas with the added potential benefits of flare mitigation and production of gasoline with a lower carbon intensity than conventional gasoline. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company's expectations and any future financial performance, the Company's strategy, future operations, financial position, prospects, plans, goals and objectives of management are forward-looking statements. The words 'could,' 'should,' 'would,' 'will,' 'aim,' 'may,' 'focus,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'advance,' 'project,' 'plan,' 'potential,' "goal,' 'strategy,' 'proposed,' 'positions,' the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. The Company cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the Company's control. These risks and uncertainties include, but are not limited to: changes in general economic, financial, legal, political and business conditions; changes in domestic and foreign markets; the failure of Verde to develop its first commercial facility, whether due to the inability to obtain the required financing or for any other reason; the failure of Verde to develop any additional commercial facility for any reason; the risks and uncertainties relating to the implementation of Verde's business strategy and the timing of any business milestone; and delays in acquisition, financing, construction and development of any potential projects. Should one or more of the risks or uncertainties described herein and in any oral statements made in connection therewith occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. There may be additional risks that the Company presently does not know or that the Company currently believes are immaterial that could cause actual results to differ from those contained in the forward-looking statements. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in the Company's filings with the Securities and Exchange Commission (the 'SEC'). The Company's filings with the SEC are available publicly on the SEC's website at VERDE CLEAN FUELS, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) As of June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 62,054,765 $ 19,044,067 Restricted cash 100,000 100,000 Accounts receivable – other 1,009,197 226,157 Prepaid expenses and other current assets 809,318 804,186 Total current assets 63,973,280 20,174,410 Non-current assets: Property, plant and equipment, net 2,315,784 1,096,270 Intellectual property and patented technology 1,925,151 1,925,151 Operating lease right-of-use assets, net 351,754 215,806 Deposits 160,669 160,669 Total non-current assets 4,753,358 3,397,896 Total assets $ 68,726,638 $ 23,572,306 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,814,373 $ 734,374 Accrued liabilities 751,223 1,907,165 Operating lease liabilities 328,198 153,917 Other current liabilities 39,252 15,129 Total current liabilities 2,933,046 2,810,585 Non-current liabilities: Operating lease liabilities 45,742 78,245 Total non-current liabilities 45,742 78,245 Total liabilities 2,978,788 2,888,830 Commitments and Contingencies Stockholders' equity Class A common stock, par value $0.0001 per share, 22,049,621 and 9,549,621 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 2,205 955 Class C common stock, par value $0.0001 per share, 22,500,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 2,250 2,250 Additional paid in capital 62,797,055 37,502,903 Accumulated deficit (29,763,927 ) (27,257,086 ) Noncontrolling interest 32,710,267 10,434,454 Total stockholders' equity 65,747,850 20,683,476 Total liabilities and stockholders' equity $ 68,726,638 $ 23,572,306 Expand
